Press coverage about BioSpecifics Technologies (NASDAQ:BSTC) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioSpecifics Technologies earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.6394744618693 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of BioSpecifics Technologies in a report on Thursday, July 5th. BidaskClub raised shares of BioSpecifics Technologies from a “strong sell” rating to a “sell” rating in a report on Friday, June 22nd. Zacks Investment Research downgraded shares of BioSpecifics Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, ValuEngine raised shares of BioSpecifics Technologies from a “sell” rating to a “hold” rating in a report on Thursday, July 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. BioSpecifics Technologies presently has a consensus rating of “Hold” and an average target price of $59.00.

Shares of BioSpecifics Technologies traded up $0.19, reaching $46.72, during midday trading on Wednesday, Marketbeat reports. 17,654 shares of the company’s stock were exchanged, compared to its average volume of 26,106. The company has a market capitalization of $340.38 million, a price-to-earnings ratio of 27.50 and a beta of 1.46. BioSpecifics Technologies has a 12 month low of $38.05 and a 12 month high of $53.77.

BioSpecifics Technologies (NASDAQ:BSTC) last released its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.05). The business had revenue of $7.09 million for the quarter, compared to the consensus estimate of $7.97 million. BioSpecifics Technologies had a return on equity of 18.92% and a net margin of 44.57%. equities research analysts predict that BioSpecifics Technologies will post 2.09 earnings per share for the current fiscal year.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names.

Insider Buying and Selling by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with's FREE daily email newsletter.